Sofosbuvir-Containing Hepatitis C Products/Rifabutin Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Very Serious. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Rifabutin may decrease the amount of hepatitis C medicine your body absorbs.
What might happen:
The amount of hepatitis C medicine in your blood may decrease and it may not work as well.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know right away that you are taking these medicines together or if you have recently taken rifabutin.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Harvoni (ledipasvir and sofosbuvir) Australian Product Information. Gilead Sciences Pty Ltd June 20, 2019.
- 2.Harvoni (ledipasvir and sofosbuvir) Canadian prescribing information. Gilead Sciences Canada, Inc. June 27, 2019.
- 3.Harvoni (ledipasvir and sofosbuvir) UK Summary of Product Characteristics. Gilead Sciences Ltd July, 2020.
- 4.Harvoni (ledipasvir and sofosbuvir) US prescribing information. Gilead Sciences November, 2019.
- 5.Epclusa (sofosbuvir and velpatasvir) Australian product information. Gilead Sciences Pty Ltd June 21, 2019.
- 6.Epclusa (sofosbuvir and velpatasvir) Canadian prescribing information. Gilead Sciences Canada, Inc. June 26, 2019.
- 7.Epclusa (sofosbuvir and velpatasvir) UK Summary of Product Characteristics. Gilead Sciences Ltd September 2, 2019.
- 8.Epclusa (sofosbuvir and velpatasvir) US prescribing information. Gilead Sciences, Inc. April, 2022.
- 9.Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Australian product information. Gilead Sciences Pty Ltd June 21, 2019.
- 10.Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Canadian prescribing information. Gilead Sciences Canada, Inc. June 26, 2019.
- 11.Vosevi (sofosbuvir/velpatasvir/voxilaprevir) UK Summary of Product Characteristics. Gilead Sciences Ltd September 3, 2019.
- 12.Vosevi (sofosbuvir/velpatasvir/voxilaprevir) US prescribing information. Gilead Sciences, Inc. September, 2019.
- 13.European Medicines Agency (EMA). Harvoni : EPAR - Procedural steps taken and scientific information after the authorisation. Accessed at: https://www.ema.europa.eu/en/documents/procedural-steps-after/harvoni-epa r-procedural-steps-taken-scientific-information-after-authorisation_en.pd f August 5, 2019.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.